NVCR
NovoCure Limited
Healthcare — Medical Devices
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Price History
Fundamentals
| Market Cap | $1.73B |
| P/E Ratio (TTM) | - |
| Forward P/E | -16.22 |
| EPS (TTM) | $-1.27 |
| Dividend Yield | - |
| Profit Margin | -21.25% |
| Revenue Growth | 15.60% |
| ROE | -43.22% |
| Debt/Equity | 69.04 |
| Recommendation | Buy 2.0 |
| Analyst Target | $27.14 |
| Analysts | 7 |
| Next Earnings | Oct 29, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 44.8 |
| Beta | 0.94 |
| SMA 20 | $16.49 |
| SMA 40 | $16.37 |
| 52-Week High | $21.45 |
| 52-Week Low | $9.82 |
| 50-Day Avg | $16.53 |
| 200-Day Avg | $13.79 |
| Avg Volume | $1.79M |
| Volume | $1.19M |
Performance Analysis
NEUTRALNVCR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 05:07 UTC
Back to Screener Export Report